Shares of Relmada Therapeutics Inc. (RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, are down more than 50% from their 52-week high of $7.22, recorded in March of this year, and trade around $3.45.
The company's lead investigational program is REL-1017, a novel NMDA receptor channel blocker, being developed as an adjunctive treatment for major depressive disorder (MDD).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com